YOUR SEARCH FOR Text 17 RESULTS
1 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… data for its selective inhibitor of CDK2 (INCB123667), which demonstrated its potential … for late-stage cancers. In a Phase 1 study of INCB123667, early clinical activity was observed …
2 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… INCB99318 based on positive therapeutic ratios. INCB123667 (CDK2): In the cell cycle, the serine … (cell growth) to the S-phase (DNA replication). INCB123667 is a novel, potent and selective oral …
3 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs May 2, 2023 at 7:00 AM EDT PDF
4 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… colorectal cancer (MSS CRC) was initiated. INCB123667 (CDK2i) In the fourth quarter 2025, … MAESTRA-1, a Phase 2 single-arm study of INCB123667 in patients with platinum-resistant …
5 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… clinical candidates is summarized below. INCB123667 (CDK2): INCB123667 is a novel, potent and selective oral …
6 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… its selective small molecule inhibitor of CDK2 (INCB123667), which demonstrated its potential … for late-stage cancers. In a Phase 1 study of INCB123667, early clinical activity was observed …
7 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… for patients with SCAC. Phase 1 data of INCB123667, a highly selective and potentially … overexpress Cyclin E1. The Phase 1 trial of INCB123667 in combination with other agents is …
8 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation and Autoimmunity
… Non-small cell lung cancer status for mobile INCB123667 CDK2 PROC with cyclin E1 overexpression status for mobile INCB123667 CDK2 Solid tumors status for mobile …
9 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… its potentially first-in-class CDK2 inhibitor (INCB123667), in ovarian cancer in 2025 and is also evaluating INCB123667 in combination with other treatments. …
10 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… its potentially first-in-class CDK2 inhibitor (INCB123667), in ovarian cancer in 2025 and is also evaluating INCB123667 in combination with other treatments. …